FIELD: chemistry.
SUBSTANCE: invention relates to a crystalline form of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole meglumine, wherein said crystalline form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) 10.7 ± 0.2, 11.8 ± 0.2, 13.3 ± 0.2, 14.8 ± 0.2, 17.9 ± 0.2, 21.4 ± 0.2 and 21.7 ± 0.2. Invention also relates to a pharmaceutical composition that inhibits dissociation of TTR, comprising a therapeutically effective amount of said crystalline form and to a method for treatment of transthyretin-mediated amyloidosis in a mammal.
EFFECT: technical result is a crystalline form 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole meglumine having improved process properties, in particular improved stability.
8 cl, 24 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CRYSTALLINE SOLID FORMS OF 6-CARBOXY-2-(3,5-DICHLOROPHENYL)BENZOXAZOLE | 2015 |
|
RU2692252C2 |
| SALTS AND POLYMORPHS OF 8-FLUORO-2-{4-[(METHYLAMINO)METHYL]PHENYL}-1,3,4,5-TETRAHYDRO-6H-AZEPINO[5,4,3-cd]INDOL-6-ONE | 2011 |
|
RU2570198C2 |
| CRYSTALLINE FORMS OF 6-[2-(METHYLCARBAMOYL)PHENYLSULFANYL]-3-E-[2-(PYRIDIN-2-YL)ETHENYL]INDAZOLE, SUITABLE FOR TREATMENT OF ABNORMAL GROWTH OF CELLS IN MAMMALS | 2008 |
|
RU2518898C2 |
| CRYSTALLINE FORMS OF [R[(R*,R*)]-2-(4-FLUOROPHENYL)-BETA,DELTA-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROL-1-HEPTANOIC ACID | 2004 |
|
RU2315755C2 |
| CRYSTALLINE FORMS OF 1-((2R,4R)-2-(1H-BENZO[D]IMIDAZOL-2-YL)-1-METHYLPIPERIDIN-4-YL)-3-(4-CYANOPHENYL)UREA MALEATE | 2016 |
|
RU2717564C2 |
| STABLE FORMULATIONS OF IMANITIB | 2008 |
|
RU2470641C2 |
| SALTS AND POLYMORPHIC MODIFICATIONS OF THE INHIBITOR VEGF-R | 2006 |
|
RU2369607C1 |
| MOTILIDE POLYMORPHS | 2007 |
|
RU2422453C2 |
| POLYMORPHIC FORM | 2009 |
|
RU2448966C1 |
| CRYSTALLINE FORM OF VINFLUNINE DITARTRATE | 2006 |
|
RU2426735C2 |
